149 related articles for article (PubMed ID: 24999678)
1. Somatostatin receptor imaging-guided pasireotide therapy in medullary thyroid cancer with ectopic adrenocorticotropin production.
Verburg FA; Anlauf M; Mottaghy FM; Karges W
Clin Nucl Med; 2015 Jan; 40(1):e83-4. PubMed ID: 24999678
[TBL] [Abstract][Full Text] [Related]
2. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
3. Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.
Hayes AR; Crawford A; Al Riyami K; Tang C; Bomanji J; Baldeweg SE; Wild D; Morganstein D; Harry A; Grozinsky-Glasberg S; Oleinikov K; Khoo B; Caplin ME; Nicolas GP; Grossman AB
J Clin Endocrinol Metab; 2021 Nov; 106(12):e4903-e4916. PubMed ID: 34379772
[TBL] [Abstract][Full Text] [Related]
4. ECTOPIC CUSHING SYNDROME: A 10-YEAR EXPERIENCE FROM A TERTIARY CARE CENTER IN SOUTHERN INDIA.
Sathyakumar S; Paul TV; Asha HS; Gnanamuthu BR; Paul MJ; Abraham DT; Rajaratnam S; Thomas N
Endocr Pract; 2017 Aug; 23(8):907-914. PubMed ID: 28614007
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
6. Medullary thyroid carcinoma - PET/CT imaging with 68Ga-labelled gastrin and somatostatin analogues.
Kunikowska J; Ziemnicka K; Pawlak D; Ruchała M; Kolasa A; Janicka-Jedyńska M; Woźniak A; Mikołajczak R; Królicki L
Endokrynol Pol; 2016; 67(1):68-71. PubMed ID: 26884118
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of
Tuncel M; Kılıçkap S; Süslü N
Ann Nucl Med; 2020 Sep; 34(9):663-674. PubMed ID: 32602032
[TBL] [Abstract][Full Text] [Related]
8. 68Ga DOTANOC PET/CT detects medullary thyroid cancer relapse at bone level.
Nicolini S; Ambrosini V; Fantini L; Fanti S
Clin Nucl Med; 2012 Jun; 37(6):591-2. PubMed ID: 22614194
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
10. The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (⁶⁸Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC).
Pałyga I; Kowalska A; Gąsior-Perczak D; Tarnawska-Pierścińska M; Słuszniak J; Sygut J; Góźdź S
Endokrynol Pol; 2010; 61(5):507-11. PubMed ID: 21049467
[TBL] [Abstract][Full Text] [Related]
11. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
12. Metastatic melanoma to the thyroid gland expressing somatostatin receptors-imaging with 68Ga-DOTANOC PET/CT.
Jung RS; Mittal BR; Bal A; Dey P; Shukla J; Kapoor R
Clin Nucl Med; 2015 Feb; 40(2):175-6. PubMed ID: 25546189
[TBL] [Abstract][Full Text] [Related]
13. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues.
Cano JM; Galán R; López R
Thyroid; 2017 Nov; 27(11):1450-1455. PubMed ID: 28927353
[TBL] [Abstract][Full Text] [Related]
14. Incidental Detection of Medullary Thyroid Carcinoma by 68Ga-DOTATATE PET/CT in a Patient With Neuroendocrine Tumor Liver Metastases.
Mahajan S; Shaha A; Grewal RK
Clin Nucl Med; 2018 Feb; 43(2):136-138. PubMed ID: 29261627
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
[TBL] [Abstract][Full Text] [Related]
17. Changes in biodistribution on
Cherk MH; Kong G; Hicks RJ; Hofman MS
Cancer Imaging; 2018 Jan; 18(1):3. PubMed ID: 29361984
[TBL] [Abstract][Full Text] [Related]
18. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism.
Traub-Weidinger T; Putzer D; von Guggenberg E; Dobrozemsky G; Nilica B; Kendler D; Bale R; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1995-2001. PubMed ID: 26173620
[TBL] [Abstract][Full Text] [Related]
19. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases.
Castroneves LA; Coura Filho G; de Freitas RMC; Salles R; Moyses RA; Lopez RVM; Pereira MAA; Tavares MR; Jorge AAL; Buchpiguel CA; Hoff AO
J Clin Endocrinol Metab; 2018 Sep; 103(9):3250-3259. PubMed ID: 29846642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
